Search
for
Sort by
Research 211–240 of 376
- Cold thermal injury from cold caps used for the prevention of chemotherapy-induced alopecia
- Anticancer effects of metformin on neuroendocrine tumor cells in vitro
- Current Status of PRP Manufacturing Requirements & European Regulatory Frameworks: Practical Tools for the Appropriate Implementation of PRP Therapies in Musculoskeletal Regenerative Medicine
- Human Hair Graying Revisited: Principles, Misconceptions, and Key Research Frontiers
- Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
- Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
- Social media for arthritis-related comparative effectiveness and safety research and the impact of direct-to-consumer advertising
- The Dermatology Life Quality Index (DLQI) used as the benchmark in validation of 101 quality‐of‐life instruments: A systematic review
- Commonalities Between COVID-19 and Radiation Injury
- Major Differences in Expression of Inflammatory Pathways in Skin from Different Body Sites of Healthy Individuals
- Bullying in persons with skin diseases
- Hidradenitis Suppurativa and Comorbid Disorder Biomarkers, Druggable Genes, New Drugs and Drug Repurposing—A Molecular Meta-Analysis
- Research Relevant Conditions and Pathology in Nonhuman Primates
- Ptosis in childhood
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata
- Prophylaxis and Management of Skin Toxicities
- Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
- Presumptive Albendazole Toxicosis in 12 Alpacas
- The ATP sensitive potassium channel (KATP) is a novel target for migraine drug development
- Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
- Molecular Targeted Agents and Biologic Therapies for Non-small Cell Lung Cancer
- Hair regrowth in alopecia areata and re‐pigmentation in vitiligo in response to treatment: Commonalities and differences
- Epidemiology of Vitiligo – A Dual Population-Based Approach
- Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis (Market Research Study Sponsored by Eli Lilly and Company) in Patients on Palliative Treatment for Advanced Breast Cancer
- Use of topical clascoterone for the treatment of hidradenitis suppurativa
- The burden of alopecia areata: A scoping review focusing on quality of life, mental health and work productivity
- Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
- ‘Dr. Google, What Is That on My Skin?’—Internet Searches Related to Skin Problems: Google Trends Data from 2004 to 2019
- Health-related quality of life with sacituzumab govitecan in HR+/HER2− metastatic breast cancer in the phase III TROPiCS-02 trial